Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 193-199

  Noguchi, Ryuichi ^a   Yoshiji, Hitoshi ^a   Ikenaka, Yasuhide ^a   Kitade, Mitsuteru ^a   Kaji, Kosuke ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Yamazaki, Masaharu ^a   Tsujimoto, Tatsuhiro ^a   Akahane, Takemi ^a   Uemura, Masahito ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Interferon; p53; Vascular endothelial cell growth factor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD31 ANTIGEN; INTERFERON; MESSENGER RNA; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

EID: 38749107724     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.193     Document Type: Article

References (46)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
2. Iwamiya T, Sawada S and Ohta Y: Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33: S134-S138, 1994.
3. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235, 2005.
4. Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94: 435-442, 2002.
5. Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106: 1990-1997, 2006.
6. Hertzog PJ, Hwang SY and Kola I: Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 39: 226-232, 1994.
7. Poynard T, Yuen MF, Ratziu V and Lai CL: Viral hepatitis C. Lancet 362: 2095-2100, 2003.
8. Hayashi N and Takehara T: Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 41: 17-27, 2006.
9. Nishiguchi S, Shiomi S, Nakatani S, et al: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357: 196-197, 2001.
10. Shiratori Y, Ito Y, Yokosuka O, et al: Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142: 105-114, 2005.
11. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
12. Guo RP, Zhong C, Shi M, et al: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clinical Oncol 132: 547-555, 2006.
13. Iavarone M, Lampertico P, Iannuzzi F, et al: Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepatitis 14: 133-139, 2007.
14. Yoshiji H, Kuriyama S, Yoshii J, et al: Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28: 1489-1496, 1998.
15. Albini A, Marchisone C, Del Grosso F, et al: Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156: 1381-1393, 2000.
16. Rozera C, Carlei D, Lollini PL, et al: Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am J Pathol 154: 1211-1222, 1999.
17. Da Silva AJ, Brickelmaier M, Majeau GR, et al: Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 22: 173-188, 2002.
18. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K and Sugimachi K: The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 22: 1702-1707, 1995.
19. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K and Maeda S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54: 231-235, 1994.
20. Takaoka A, Hayakawa S, Yanai H, et al: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523, 2003.
21. Yoshiji H, Kuriyama S, Ways DK, et al: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59: 4413-4418, 1999.
22. Noguchi R, Yoshiji H, Kuriyama S, et al: Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9: 6038-6045, 2003.
23. Yoshii J, Yoshiji H, Kuriyama S, et al: The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 94: 768-773, 2001.
24. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35, 2001.
25. Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-842, 2002.
26. Chiang LC, Ng LT, Lin IC, Kuo PL and Lin CC: Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett 237: 207-214, 2006.
27. Yoshida H, Tateishi R, Arakawa Y, et al: Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53: 425-430, 2004.
28. Wang L, Tang ZY, Qin LX, et al: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32: 43-48, 2000.
29. Kerbel RS: Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19: S45-S51, 2001.
30. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
31. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 69 (Suppl. 3): 11-16, 2005.
32. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
33. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
34. Gollob JA, Wilhelm S, Carter C and Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392-406, 2006.
35. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
36. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N and Hayashi J: A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 33: 121-128, 2006.
37. Damdinsuren B, Nagano H, Wada H, et al: Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol 30: 201-208, 2007.
38. Matsumoto K, Okano J and Murawaki Y: Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 40: 722-732, 2005.
39. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
40. Yu JL, Rak JW, Coomber BL, Hicklin DJ and Kerbel RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526-1528, 2002.
41. Bordel R, Laschke MW, Menger MD and Vollmar B: Inhibition of p53 during physiological angiogenesis in the hamster ovary does not affect extent of new vessel formation but delays vessel maturation. Cell Tissue Res 320: 427-435, 2005.
42. Nakaji M, Yano Y, Ninomiya T, et al: IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 25: 389-397, 2004.
43. Cascinu S, Graziano F, Catalano V, et al: Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. Tumour Biol 24: 77-81, 2003.
44. Fondevila C, Metges JP, Fuster J, et al: p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer, Br J Cancer 90: 206-215, 2004.
45. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.
46. Wu WZ, Sun HC, Shen YF, et al: Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Rese Clinical Oncol 131: 169-178, 2005.